POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04826016
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Javier Cortés, MD,PhD International Breast Cancer Center (IBCC), Quiron Group, Barcelona (Spain) Principal Investigator: Peter Kaufman, MD University of Vermont Medical Center, Burlington (Vermont, USA)
Get Well Soon